Gynazole_1: profile and news

KV Pharmaceutical Reports Record Revenues for Fiscal 2006 Third ... Feb 7, 2006
Ther-Rx Revenues The Company's two unique, single-dose treatments for vaginal yeast infections and bacterial vaginosis (BV); respectively, Gynazole-1(R) and ... - PR Newswire (press release),

Hungary Richter grants exclusive marketing rights to KV ... Feb 14, 2006
Richter has been a terrific partner as demonstrated by the international licensing of our two NDA approved anti-infective products, Gynazole-1® and more ... - Portfolio.hu,

KV Pharmaceutical Company to Market New Generic Drugs in US Via ... Feb 14, 2006
Richter has been a terrific partner as demonstrated by the international licensing of our two NDA approved anti- infective products, Gynazole-1® and more ... - Yahoo! News (press release)

KV Signs Licensing Agreement for the Marketing of Clindesse(TM) in ... Dec 1, 2005
Agreement Augments Existing Partnership for the International Marketing of Gynazole-1(R) ST. LOUIS, Dec. 1 /PRNewswire-FirstCall ... - PR Newswire (press release),

KV Signs Licensing Agreement for the Marketing of Clindess in 18 ... Dec 1, 2005
Richter, which includes an international license to market KV's one-dose prescription cream treatment for vaginal yeast infection, Gynazole-1(R) (butoconazole ... - PharmaLive.com (press release),

KV Pharmaceutical Company Reports Record Revenues for Fiscal 2006 ... Nov 9, 2005
Second Quarter Highlights * Approval to market Gynazole-1(R), KV's one-dose anytime prescription cream treatment for vaginal yeast infections by KV's partner ... - PR Newswire (press release),

Richter signs licence deal with KV Pharmaceutical Dec 1, 2005
...company Richter Gedeon signed a long-term licence agreement with KV Pharmaceutical Company to distribute the US company's vaginosis medicine "Gynazole-1" in 18 ... - Portfolio.hu,

KV Pharma inks licensing deal in Eastern Europe Dec 1, 2005
Europe. Gedeon Richter already is licensed to market KV's Gynazole-1 treatment for vaginal yeast infections in Eastern Europe. Under ... - St. Louis Business Journal,

Another Prestigious International Partner in KV's Licensing ... Sep 21, 2005
...that it has signed a licensing agreement with Theramex SpA for the marketing in Italy of two of KV's top-selling women's health products, Gynazole-1(R) and ... - PR Newswire (press release),

KV Pharmaceutical Signs POA/Vitaflo Scandinavia AB to Market ... Sep 19, 2005
KV Adds To Its Prestigious International Licensing Partnerships For Gynazole-1(R) and Clindesse(TM) ST. LOUIS, Sept. 19 /PRNewswire ... - PR Newswire (press release),

KV Pharmaceutical Signs POA/Vitaflo Scandinavia AB to Market ... Sep 20, 2005
LOUIS -- KV Adds To Its Prestigious International Licensing Partnerships For Gynazole-1(R) and Clindesse(TM), KV Pharmaceutical Company (NYSE:KVa/KVb) today ... - dBusinessNews St. Louis (press release),

KV Pharmaceutical Signs POA/Vitaflo Scandinavia AB to Market ... Sep 19, 2005
Company today announced that it has concluded a licensing agreement with Vitaflo Scandinavia AB for its two NDA products, Gynazole-1(R) (butocanzole nitrate 2 ... - PharmaLive.com (press release),

KV Pharma licenses products in Scandinavia Sep 19, 2005
Under the deal, Vitaflo Scandinavia will market the Gynazole-1 treatment for yeast infections and Clindesse treatment for bacterial vaginosis in Sweden, Denmark ... - St. Louis Business Journal,

KV Pharmaceutical Announces First Asian Approval For Gynazole-1 Aug 25, 2005
...that its licensee, Pan Malayan, has received approval to market KV's one-dose prescription cream treatment for vaginal yeast infections, Gynazole-1(R), in ... - PharmaLive.com (press release),

International Approvals: Adderall XR, Gynazole-1, Leuplin SR Aug 29, 2005
Completion in August of the mutual recognition procedure for butoconazole nitrate 2% vaginal cream (Gynazole-1, made by Gedeon Richter, Ltd., under license ... - Medscape (subscription)

KV Pharmaceutical Company Announces Approvals for its Gynazole-1(R ... Aug 17, 2005
Gedeon Richter, Ltd. Licensee of Gynazole-1(R) Receives Approval to Market ST. LOUIS, Aug. 17 /PRNewswire-FirstCall/ -- KV Pharmaceutical ... - PR Newswire (press release),

KV Pharmaceutical Company Announces Approvals for its Gynazole-1(R ... Aug 18, 2005
Licensee of Gynazole-1(R) Receives Approval to Market,KV Pharmaceutical Company (NYSE:KVa/KVb) announced today that it has received notification of approvals ... - dBusinessNews St. Louis (press release),

KV Pharmaceutical Company Announces Approvals for its Gynazole-1 ... Aug 17, 2005
August 17, 2005 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company announced today that it has received notification of approvals to market Gynazole-1(R) from ... - PharmaLive.com (press release),

KV Pharmaceutical Company Announces Approvals for its Gynazole-1(R ... Aug 17, 2005
FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) announced today that it has received notification of approvals to market Gynazole-1® from one of its ... - Yahoo News (press release)

News For Your Web Site Aug 26, 2005
KV Pharmaceutical Announces First Asian Approval For Gynazole-1(R) - KV Partner - Pan Malayan Receives Approval to Market in Singapore. ST. ... - dBusinessNews St. Louis (press release),

Singaporean approval for Pan Malayan Aug 26, 2005
Pan Malayan has received permission to market its one-dose prescription cream treatment for vaginal yeast infections, Gynazole-1, in Singapore. ... - Pharmaceutical Business Review

KV Pharmaceutical Company Reports Fiscal 2006 First Quarter ... Aug 10, 2005
Growth was led by Ther-Rx's second NDA product, Clindesse(TM), with 139,368 total scripts filled since launch, Gynazole-1(R), with total prescription volume up ... - PharmaLive.com (press release),

Licensee to market KV Pharma product in Asia Aug 25, 2005
Singapore. The approval was the first for Gynazole-1, a one-dose prescription cream for vaginal yeast infections, in the Asian region. ... - St. Louis Business Journal,

KV licensee to market product in Eastern Europe Aug 17, 2005
Under the approval, Gedeon Richter will market KV's Gynazole-1 in the 15 of its 21 countries, which represent a market for vaginal anti-infectives of about $60 ... - St. Louis Business Journal, <**results**>

KV Pharmaceutical Company Reports Fiscal 2005 Results Jun 14, 2005
As of the end of fiscal 2005, Ther-Rx's Gynazole-1(R) had captured a 32% share of the prescription vaginal anti-fungal cream marketplace according to IMS, up ... - PR Newswire (press release)

KV Pharmaceutical Company Licenses Two Women's Health Products for ... Mar 31, 2005
KV Signs Agreement with ISDIN, SA (Esteve/Puig) Covering Market Leader Gynazole-1(R) and Recently Approved Clindesse(TM) ST. LOUIS ... - PR Newswire

KV Pharmaceutical Company Licenses Two Women's Health Products for ... Mar 31, 2005
...of licensing rights in Spain, Portugal and Andorra for KV's two single-dose treatment prescription vaginal cream products, US market leader Gynazole-1(R) and ... - PharmaLive.com

KV inks licensing deal with Spanish pharmaceutical firm Mar 31, 2005
Under the deal, KV will receive liscensing fees and manufacturing revenue for its Gynazole-1 and Clindesse products. Gynazole-1 ... - St. Louis Business Journal,

KV Pharmaceutical Signs Second International Licensing Agreement ... Mar 9, 2005
...the first of KV's nearly 60 international partners to launch KV's one-dose prescription vaginal antifungal cream treatment for candidiasis, Gynazole-1(R), is ... - PR Newswire (press release)

KV Pharma licenses women's prescription product in Brazil Mar 9, 2005
Sigma Pharma already markets KV's Gynazole-1 prescription vaginal anti-infective product in Brazil and has a 19 percent share of the market in less than two ... - St. Louis Business Journal,